Herceptin Prolongs Progression Free Survival Of HER2 Breast Cancer Patients
Friday, May 30th, 2008The results of a phase III trial comparing Herceptin with chemo against chemo on its own showed that Herceptin helped women with aggressive metastatic HER2-positive breast cancer live nearly three months longer without their cancer progressing. The findings are being presented this weekend at the 44th annual meeting of the ...